Affiliation:
1. Department of Hematology and Medical Oncology Taussig Cancer Center, Cleveland Clinic Cleveland Ohio USA
Abstract
The role of the proteasome inhibitor ixazomib in the treatment of POEMS syndrome continues to evolve. He and colleagues present the results of a study investigating ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed POEMS patients. The triplet showed excellent efficacy and tolerability, and constitutes an effective treatment option for patients with POEMS.Commentary on: He et al. An open‐label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly‐diagnosed POEMS syndrome. Br J Haematol 2024;205:478‐482.